Classic Hodgkin lymphoma (cHL) is a highly curable lymphoma that primarily affects younger patients. The therapeutic landscape has evolved and generally consists of varying combinations of chemotherapy and immunotherapy as well as radiation in selected cases. While most patients are cured of their lymphoma, there is a risk of late treatment-related cardiotoxicity that impacts long-term survival and quality of life in this population. Careful consideration of baseline cardiac function and risk factors should be undertaken prior to proceeding with anthracycline-based therapies or thoracic radiation, as adjuvant cardiac-focused efforts may serve to mitigate the risk of cardiovascular dysfunction in this population. This review outlines the evidence supporting current recommendations for assessing baseline cardiotoxicity risk, implementing risk reduction strategies and treatment modifications, the role of multidisciplinary evaluation in high-risk patients, and strategies for long-term cardiac monitoring to minimize treatment related cardiac morbidity and mortality.
JACC CardioOncology Editor-in-Chief and CME Editor
Bonnie Ky, MD, MSCE, FACC
Authors
Hari S. Raman, MD
Joshua Mitchell, MD, MSCI, FACC, FICOS
Anju Nohria, MD, MSc
Jenica N. Upshaw, MD, MsC
AnnS. Lacasce, MD, MMSc
Important Dates
Date of Release: December 16, 2025
Term of Approval/Date of CME/MOC Expiration: December 15, 2026